Advertisement

Huntington's disease, behavioral disturbances, and kynurenines: Preclinical findings and therapeutic perspectives

  • László Vécsei
    Correspondence
    Address reprint requests to László Vécsei, M.D., Department of Neurology, Szent-Györgyi University Medical School, POB 397, Szeged, H-6701, Hungary.
    Affiliations
    Department of Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
    Search for articles by this author
  • M. Flint Beal
    Affiliations
    Neurology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beal MF
        • Marshall PE
        • Bird ED
        • Landis DMD
        • Martin JB
        Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease.
        Brain Res. 1985; 361: 135-145
        • Beal MF
        • Kowall NW
        • Ellison DW
        • Mazurek MF
        • Swartz KJ
        • Martin JB
        Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
        Nature. 1986; 321: 168-171
        • Beal MF
        • Kowall NW
        • Swartz KJ
        • Ferrante RJ
        • Martin JB
        Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
        Synapse. 1989; 31: 38-47
        • Beal MF
        • Matson WR
        • Swartz KJ
        • Gamache P
        • Bird ED
        Kynurenine pathway measurements in Huntington's disease striatum: Evidence for reduced formation of kynurenic acid.
        J Neurochem. 1990; 55: 1327-1339
        • Beal MF
        Neurochemistry and toxin models in Huntington's disease.
        Curr Opin Neurol. 1994; 7: 542-547
        • Coyle JT
        • Schwarcz R
        Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea.
        Nature. 1976; 263: 244-246
        • Folstein SE
        • Franz ML
        • Jensen BA
        • Chase GA
        • Folstein MF
        Conduct disorder and affective disorder among the offspring of patients with Huntington's disease.
        Psychol Med. 1983; 13: 45-52
        • Folstein SE
        • Abbott MH
        • Chase GA
        • Jensen BA
        • Folstein MF
        The association of affective disorder with Huntington's disease in a case series and in families.
        Psychol Med. 1993; 13: 537-542
        • Hantraye P
        • Riche D
        • Isacson O
        A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon.
        Exp Neurol. 1990; 108: 91-104
        • Heidelberger C
        • Gulberg ME
        • Morgan AF
        • Lepkovsky S
        Tryptophan metabolism I: Concerning the mechanism of the mammalian conversation of tryptophan into kynurenine, kynurenic acid and nicotinic acid.
        J Biol Chem. 1949; 179: 143-150
        • Köhler C
        • Schwarcz R
        Comparison of ibotenate and kainate neurotoxicity in rat brain.
        Neuroscience. 1983; 8: 819-835
        • Martin JB
        • Gusella JF
        Huntington's disease.
        N Engl J Med. 1986; 315: 1267-1276
        • McGeer EG
        • McGeer PL
        Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids.
        Nature. 1976; 263: 517-519
        • Nozaki K
        • Beal MF
        Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats.
        J Cerebral Blood Flow Metabol. 1992; 12: 400-407
        • Podolsky S
        • Leopold NA
        Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease.
        Gerontology. 1977; 23: 55-63
        • Sanberg PR
        • Calderon SF
        • Giordano M
        • Tew JM
        • Norman AB
        The quinolinic acid model of Huntington's disease: Locomotor abnormalities.
        Exp Neurol. 1989; 105: 45-53
        • Schwarcz R
        • Whetsell WO
        • Mangano RM
        Quinolinic acid: An endogenous metabolite that produces axon-sparing lesion in rat brain.
        Science. 1983; 219: 316-318
        • Schwarcz R
        • Foster HC
        • French ED
        • Whetsell WE
        • Köhler C
        Excitotoxic models of neurodegenerative disorders.
        Life Sci. 1984; 35: 19-32
        • Stone TW
        • Connick JH
        Quinolinic acid and other kynurenines in the central nervous system.
        Neuroscience. 1985; 15: 597-617
        • Stone TW
        Neuropharmacology of quinolinic and kynurenic acids.
        Pharmacol Rev. 1993; 45: 309-379
        • Storey E
        • Cipolloni PB
        • Ferrante RJ
        • Kowall NW
        • Beal MF
        Movement disorder following excitotoxin lesions in primates.
        NeuroReport. 1994; 5: 1259-1261
        • Vécsei L
        • Beal MF
        Influence of kynurenine treatment on open-field activity, elevated plus maze, avoidance behaviors and seizures in rats.
        Pharmacol Biochem Behav. 1990; 37: 71-76
        • Vécsei L
        • Beal MF
        Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats.
        Brain Res Bull. 1990; 25: 623-627
        • Vécsei L
        • Beal MF
        Comparative behavioral and neurochemical studies with striatal kainic acid or quinolinic acid lesioned rats.
        Pharmacol Biochem Behav. 1991; 39: 473-478
        • Vécsei L
        • Beal MF
        Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats.
        Eur J Pharmacol. 1991; 196: 239-246
        • Vécsei L
        • Beal MF
        Behavioral and pharmacological effects of centrally administered aminooxyacetic acid in rats.
        Eur J Pharmacol. 1992; 220: 259-262
        • Vécsei L
        • Miller J
        • MacGarvey U
        • Beal MF
        Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain.
        Brain Res Bull. 1992; 28: 233-238
        • Vécsei L
        • Miller J
        • MacGarvey U
        • Beal MF
        Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid.
        Neurodegeneration. 1992; 1: 17-26
        • Vécsei L
        • Freese A
        • Swartz KJ
        • Beal MF
        Neurological Disorders: Novel Experimental and Therapeutic Strategies.
        Ellis Horwood, New York1992